Cogent Biosciences, Inc. Operating Cash Flow
Cogent Biosciences, Inc. (COGT) reported Operating Cash Flow of -$164.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- Cogent Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$77.27M.
- Cogent Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$86.88M.
- Cogent Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$79.11M.
- Cogent Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$64.29M.
- Cogent Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$264.44M.
- Cogent Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$207.79M.
- Cogent Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$153.62M.
- Cogent Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$118.64M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$77.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$164.15M 10-Q · filed 2026-08-10 | -$243.26M derived: sum of 3 quarters · filed 2026-08-10 | -$307.55M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$86.88M 10-Q · filed 2026-05-05 | -$165.99M derived: sum of 2 quarters · filed 2026-05-05 | -$230.27M derived: sum of 3 quarters · filed 2026-05-05 | -$284.82M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$79.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$143.39M derived: sum of 2 quarters · filed 2026-02-17 | -$197.93M derived: sum of 3 quarters · filed 2026-08-10 | -$264.44M 10-K · filed 2026-02-17 |
| 2025-09-30 | -$64.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$118.83M derived: sum of 2 quarters · filed 2026-08-10 | -$185.34M 10-Q · filed 2025-11-07 | -$245.92M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$54.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$121.05M 10-Q · filed 2026-08-10 | -$181.63M derived: sum of 3 quarters · filed 2026-08-10 | -$233.61M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$66.51M 10-Q · filed 2026-05-05 | -$127.09M derived: sum of 2 quarters · filed 2026-05-05 | -$179.07M derived: sum of 3 quarters · filed 2026-05-05 | -$221.77M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$60.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$112.56M derived: sum of 2 quarters · filed 2026-02-17 | -$155.26M derived: sum of 3 quarters · filed 2026-02-17 | -$207.79M 10-K · filed 2026-02-17 |
| 2024-09-30 | -$51.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$94.69M derived: sum of 2 quarters · filed 2025-11-07 | -$147.21M 10-Q · filed 2025-11-07 | -$191.28M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | -$42.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$95.23M 10-Q · filed 2025-08-05 | -$139.30M derived: sum of 3 quarters · filed 2026-02-17 | -$177.27M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | -$52.53M 10-Q · filed 2025-05-06 | -$96.60M derived: sum of 2 quarters · filed 2026-02-17 | -$134.57M derived: sum of 3 quarters · filed 2026-02-17 | -$166.64M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | -$44.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$82.04M derived: sum of 2 quarters · filed 2026-02-17 | -$114.11M derived: sum of 3 quarters · filed 2026-02-17 | -$153.62M 10-K · filed 2026-02-17 |
| 2023-09-30 | -$37.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$70.04M derived: sum of 2 quarters · filed 2024-11-12 | -$109.55M 10-Q · filed 2024-11-12 | -$138.96M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$32.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$71.58M 10-Q · filed 2024-08-06 | -$100.99M derived: sum of 3 quarters · filed 2025-02-25 | -$135.43M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$39.52M 10-Q · filed 2024-05-07 | -$68.92M derived: sum of 2 quarters · filed 2025-02-25 | -$103.36M derived: sum of 3 quarters · filed 2025-02-25 | -$129.82M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$29.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$63.85M derived: sum of 2 quarters · filed 2025-02-25 | -$90.30M derived: sum of 3 quarters · filed 2025-02-25 | -$118.64M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$34.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$60.90M derived: sum of 2 quarters · filed 2023-11-07 | -$89.23M 10-Q · filed 2023-11-07 | -$110.01M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$26.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$54.79M 10-Q · filed 2023-08-08 | -$75.57M derived: sum of 3 quarters · filed 2024-02-26 | -$89.68M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$28.33M 10-Q · filed 2023-05-09 | -$49.11M derived: sum of 2 quarters · filed 2024-02-26 | -$63.22M derived: sum of 3 quarters · filed 2024-02-26 | -$75.73M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$20.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$34.89M derived: sum of 2 quarters · filed 2024-02-26 | -$47.40M derived: sum of 3 quarters · filed 2024-02-26 | -$58.76M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$14.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$26.62M derived: sum of 2 quarters · filed 2022-11-14 | -$37.99M 10-Q · filed 2022-11-14 | -$47.35M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$12.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$23.88M 10-Q · filed 2022-08-09 | -$33.24M derived: sum of 3 quarters · filed 2022-08-09 | -$43.51M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$11.37M 10-Q · filed 2022-05-10 | -$20.73M derived: sum of 2 quarters · filed 2022-05-10 | -$31.00M derived: sum of 3 quarters · filed 2022-05-10 | -$39.32M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$9.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$19.63M derived: sum of 2 quarters · filed 2022-03-15 | -$27.96M derived: sum of 3 quarters · filed 2022-03-15 | -$35.85M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$10.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$18.59M derived: sum of 2 quarters · filed 2021-11-10 | -$26.48M 10-Q · filed 2021-11-10 | -$34.93M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$8.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$16.22M 10-Q · filed 2021-08-16 | -$24.66M derived: sum of 3 quarters · filed 2021-08-16 | -$34.87M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$7.89M 10-Q · filed 2021-05-12 | -$16.34M derived: sum of 2 quarters · filed 2021-05-12 | -$26.55M derived: sum of 3 quarters · filed 2021-05-12 | -$37.89M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | -$8.45M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$18.65M derived: sum of 2 quarters · filed 2021-03-16 | -$30.00M derived: sum of 3 quarters · filed 2021-03-16 | -$41.51M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$10.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$21.55M derived: sum of 2 quarters · filed 2020-11-09 | -$33.07M 10-Q · filed 2020-11-09 | -$42.09M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$11.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$22.86M 10-Q · filed 2020-08-11 | -$31.88M derived: sum of 3 quarters · filed 2020-08-11 | -$39.46M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | -$11.52M 10-Q · filed 2020-05-11 | -$20.54M derived: sum of 2 quarters · filed 2020-05-11 | -$28.11M derived: sum of 3 quarters · filed 2020-05-11 | -$36.03M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | -$9.02M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$16.59M derived: sum of 2 quarters · filed 2020-03-26 | -$24.51M derived: sum of 3 quarters · filed 2020-03-26 | -$32.49M 10-K · filed 2020-03-26 |
| 2018-09-30 | -$7.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$15.49M derived: sum of 2 quarters · filed 2019-11-12 | -$23.47M 10-Q · filed 2019-11-12 | -$29.98M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$7.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$15.89M 10-Q · filed 2019-08-12 | -$22.41M derived: sum of 3 quarters · filed 2019-08-12 | -$28.70M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | -$7.98M 10-Q · filed 2019-05-13 | -$14.50M derived: sum of 2 quarters · filed 2019-05-13 | -$20.79M derived: sum of 3 quarters · filed 2019-05-13 | |
| 2017-12-31 | -$6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | -$12.81M derived: sum of 2 quarters · filed 2019-03-28 | -$25.84M 10-K · filed 2019-03-28 | |
| 2017-09-30 | -$6.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$19.32M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | -$13.03M 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |